Just Food14h agobearish
US judge cuts Beyond Meat trademark penaltyThe case dates to 2022, with Sonate alleging Beyond Meat’s ad campaign with Dunkin’ Donuts was likely to confuse consumers.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
Motley Fool21d agobearish
Why Beyond Meat Stock Slumped Last MonthYou'd sink too if you effected a major reverse stock split.
24/7 Wall St.38d agobearish
Beyond Meat Falls 11% on 1-for-30 Reverse Split Reaction, Oatly SlipsBeyond Meat's 1-for-30 reverse stock split was supposed to solve a Nasdaq compliance problem, but the stock keeps falling anyway, and the company itself says there is no guarantee it stays listed.
Stocktwits43d agobearish
Why Did BYND, APP, ONON Stocks Plunge To 52-Week Lows Today?Weak results, a reverse split, analyst downgrades, and slowing growth concerns triggered sharp investor sell-offs.
Zacks57d agobearish
Pilgrim's Pride (PPC) Q2 Earnings and Revenues Miss EstimatesPilgrim's Pride (PPC) delivered earnings and revenue surprises of -14.67% and -5.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Motley Fool58d agobearish
Beyond Meat Has Dropped 32% This Year. Generational Opportunity or Falling Knife?Beyond Meat hopes it can stem its multiyear sales decline.
Moneywise109d agobearish
Infamous short seller's fraud conviction has spooked other shorters — and experts warn the industry may go silentLeft’s guilty verdict is forcing a rethink across the short-selling world as activist strategies come under fire.
StockStory141d agobearish
Beyond Meat (NASDAQ:BYND) Misses Q1 CY2026 Sales Expectations, Stock DropsPlant-based protein company Beyond Meat (NASDAQ:BYND) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 15.3% year on year to $58.21 million. Next quarter’s revenue guidance of $62.5 million underwhelmed, coming in 4.6% below analysts’ estimates. Its non-GAAP loss of $0.10 per share was in line with analysts’ consensus estimates.